{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 58 of 128', 'non-compliance, i.e., number of missed IMP applications and the reason for it, must be', 'recorded in the eCRF.', '9.8.5 Trial product destruction', 'Used and unused IMPs will be destroyed by the CMO according to approved procedures', 'and/or local requirements.', '9.9 Provision for subject care following trial completion', 'In order to ensure appropriate treatment of the subjects after they have completed the trial, the', \"subjects will be treated at the investigator's discretion or referred to other physician(s)\", 'according to standard practice.', '9.10 Reporting product complaints', 'Any defects or issues with the IMP (e.g., strange colour or consistency, inadequate labelling)', 'must be reported to Global Pharmacovigilance at LEO on the trial-specific (paper) complaint', 'form within 3 days of first knowledge.', 'Critical complaints (defined as any defect, issue that has or potentially could have a serious', 'impact for the subject [e.g., SAE]) must be reported to Global Pharmacovigilance, LEO', 'within 24 hours.', 'Complaint forms should contain a detailed description of the defect, issue, including whether', 'it led to an AE. (S)AEs which occur due to a defect or issue with the IMP will be reported by', 'the investigator as described in Sections 13.3 and 13.4.', 'Refer to the trial product handling manual for information on how to update the kit status in', 'the IRT.', 'During the investigation of the product complaint, the IMP must be stored at labelled', 'conditions unless otherwise instructed; the trial site will be notified whether the IMP needs to', 'be returned for further investigation or may be destroyed.', 'Global Pharmacovigilance, LEO contact information for reporting product complaints:', 'Fax number: +45 7226 3287', 'E-mail address: drug.safety@leo-pharma.com']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 59 of 128', '10 Discontinuation and withdrawal', '10.1 General principles', 'A subject may withdraw from the trial (i.e., withdraw from treatment and protocol-defined', 'interventions) or permanently discontinue trial treatment (i.e., stop treatment only, but agree', 'to continued protocol-defined interventions) at any time (prior to first dose or during the', 'treatment period) if the subject, the investigator, or LEO considers that it is not in the', \"subject's best interest to continue.\", 'If a subject withdraws from the trial, he/she may request destruction of any samples taken and', \"not tested, and the investigator must document this in the subject's source documentation.\", 'Subjects who withdraw from the trial and subjects who discontinue trial treatment will not be', 'replaced.', 'Data to be recorded in the eCRF', 'The primary reasons for withdrawal from the trial, discontinuation of IMP, and not attending', 'the primary endpoint visit at Week 16, if applicable, must be recorded in the medical records', 'and on the end of trial form in the eCRF where the following options are available:', 'Lack of efficacy', 'Adverse event', 'Withdrawal by subject', 'Lost to follow-up', 'Pregnancy', 'Death', 'Other', 'If \"adverse event\\' or \\'other\\' is selected, a specification must be provided in the eCRF with a', 'clear link to the specific AE if applicable.', '10.2 IMP discontinuation rules', '10.2.1 Reasons for discontinuation of IMP', 'Subjects will discontinue IMP in the event of:', \"An AE that, in the opinion of the investigator or sponsor's medical expert,\", 'contraindicates further dosing.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 60 of 128', 'Evidence of pregnancy.', 'Initiation of rescue medication.', 'Clinically important laboratory abnormalities:', 'Alanine aminotransferase and/or aspartate aminotransferase values >3xULN', 'with total bilirubin >2xULN (unless elevated bilirubin is related to Gilbert', 'Meulengracht Syndrome).', 'Confirmed aspartate aminotransferase and/or alanine aminotransferase', '>5xULN (for more than 2 weeks).', 'It is not allowed to re-start IMP treatment after discontinuation of IMP.', '10.3 Early termination assessments', 'An end of trial form must be completed for all subjects, including subjects who withdraw', 'from the trial or discontinue IMP treatment, at their last trial visit (the early termination visit,', 'the safety follow-up visit, or the primary endpoint visit, whichever comes last).', 'Withdrawal from trial', 'Subjects, who withdraw from the trial must attend an early termination visit as soon as', 'possible after last administration of IMP (see the schedule of trial procedures [Section 4] for', 'data to be collected at an early termination visit). The investigator will review any AEs which', 'will be followed-up according to Section 13.7, if the subject agrees.', 'Discontinuation of IMP', 'Subjects, who discontinue IMP prior to Week 16 will be asked to attend an early termination', 'visit as soon as possible after last IMP application and return to the trial site for 2 additional', 'visits as indicated below. See the schedule of trial procedures (Section 4) for data to be', 'collected at these visits.', 'Subjects, who discontinue IMP prior to Week 16 will be asked to attend:', 'Early termination visit (as soon as possible after the last IMP application).', 'Safety follow-up visit (2 weeks after the last IMP application).', 'Primary endpoint visit (16 weeks after the first IMP application).']\n\n###\n\n", "completion": "END"}